Human induced pluripotent stem cell derived cardiomyocytes as well as ex vivo and in vivo models of ischemia-reperfusion injury were used to test the efficacy of ASIC1a inhibitors as pre- and post-conditioning therapeutic agents.
[Circulation]
7992332
{7992332:N5CXPCBC}
apa
50
1
164658
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
